# Caris Life Sciences, Inc.

**CAI**

Nasdaq; healthcare; SIC 8071, Services-Medical Laboratories; CIK 0002019410

# None

### No letter

3 of 14 inputs computable; 7 are required, with a score in every sleeve

| Scoreboard | |
|---|---|
| **Reliability** | 0.91 AUC<br>filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025 |
| **Peer failure rate** | 1.01% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $591M to $2.67B assets<br>total assets $1.1B |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | thin data; fortress balance sheet<br>not computable: dilution, short runway, distress |
| **Inputs computable** | 3 of 14 |
| **Graded from** | filings received through Mar 3, 2026<br>239 days before the rescan; latest periodic filing 10-Q received Aug 5, 2026 |
| **Last close** | $33.67<br>2026-10-27; market equity $9.5B; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 3, 2026*

We are a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer. We develop and commercialize innovative solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Our entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. We founded Caris in 2008 with the belief and vision that combining a vast set of consistently generated molecular information with robust data-driven insights could realize the potential of precision medicine for patients.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability** | | | | | | |
| Gross profitability | not computable | 32.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| Return on invested capital | not computable | 9.3% | | | | |
| *a prior annual debt, equity, and cash observation is required* | | | | | | |
| Accruals ratio | not computable | (6.6%) | | | | |
| *a prior annual assets observation is required* | | | | | | |
| Gross margin stability, five years | not computable | 2.8 pts | | | | |
| *five annual gross margins are required; found 0* | | | | | | |
| **Solvency, sleeve percentile 22.8** | | | | | | |
| Twelve-month failure probability | not computable | 0.07% | | | | |
| *latest liabilities, cash plus short-term investments, book equity, and shares are required* | | | | | | |
| Altman Z double-prime | (0.93) | (0.33) | | 41.2 | 751 | 2025-12-31 |
| Net debt to EBITDA | (6.17x) | 1.82x | | 4.1 | 75 | 2025-12-31 |
| Interest coverage | not computable | (4.51x) | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Current ratio | 7.85x | 2.94x | | 23.2 | 832 | 2025-12-31 |
| **Growth and financing** | | | | | | |
| Revenue growth, three-year compound | not computable | 10.1% | | | | |
| *four annual observations are required; found 1* | | | | | | |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | | |
| *four consecutive annual FCF observations are required; found 1* | | | | | | |
| Reinvestment rate | not computable | 37.1% | | | | |
| *a prior annual working-capital observation is required* | | | | | | |
| Asset growth, three years | not computable | 2.1% | | | | |
| *four annual observations are required; found 1* | | | | | | |
| Net share issuance, one year | not computable | 2.5% | | | | |
| *two annual share counts are required; found 1* | | | | | | |

## Warnings

*2 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Thin data | 3 of 14 grade factors are computable; minimum is 7 |
| Fortress balance sheet | cash minus debt is 417,824,000 USD; Altman Z is not used |

## What the price implies

*at the 2026-10-27 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (15.7%) | 7.7% | 34 |
| Distance from 52-week high | 0.0% | (28.6%) | 97 |
| EBIT to enterprise value | 0.5% | (1.5%) | 57 |
| Free cash flow yield | 0.7% | (1.0%) | 58 |
| Book value to price | 0.06 | 0.28 | 22 |
| Sales to price | 0.09 | 0.31 | 21 |
| Composite equity issuance, five years | not computable | 20.5% | |
| Relative strength against the sector, log excess return | (0.38) | (0.14) | 34 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | pass |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| Long-term leverage fell | fail |
| Current ratio improved | fail |
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | fail |
| **Cash, filings, liquidity** | |
| Cash and equivalents | n/a |
| Operating cash flow, four quarters | n/a |
| Months of runway | not finite |
| Days since last periodic filing | 84 (10-Q received Aug 5, 2026) |
| Median daily dollar volume, 63 sessions | $113.8M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | operating income | us-gaap:OperatingIncomeLoss | $45.1M | 2025-12-31 | 2026-03-03 | 10-K | 26-000016 |
| 2 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$68.1M | 2025-12-31 | 2026-03-03 | 10-K | 26-000016 |
| 3 | income tax | us-gaap:IncomeTaxExpenseBenefit | $0 | 2025-12-31 | 2026-03-03 | 10-K | 26-000016 |
| 4 | total debt | us-gaap:LongTermDebt | $378.4M | 2025-12-31 | 2026-03-03 | 10-K | 26-000016 |
| 5 | book equity | us-gaap:StockholdersEquity | $577.3M | 2025-12-31 | 2026-03-03 | 10-K | 26-000016 |
| 6 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $796.3M | 2025-12-31 | 2026-03-03 | 10-K | 26-000016 |
| 7 | net income | us-gaap:NetIncomeLoss | -$68.1M | 2025-12-31 | 2026-03-03 | 10-K | 26-000016 |
| 8 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $83.2M | 2025-12-31 | 2026-03-03 | 10-K | 26-000016 |
| 9 | assets | us-gaap:Assets | $1.1B | 2025-12-31 | 2026-03-03 | 10-K | 26-000016 |
| 10 | current assets | us-gaap:AssetsCurrent | $997.8M | 2025-12-31 | 2026-03-03 | 10-K | 26-000016 |
| 11 | current liabilities | us-gaap:LiabilitiesCurrent | $127.1M | 2025-12-31 | 2026-03-03 | 10-K | 26-000016 |
| 12 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$2.5B | 2025-12-31 | 2026-03-03 | 10-K | 26-000016 |
| 13 | liabilities | us-gaap:Liabilities | $548.4M | 2025-12-31 | 2026-03-03 | 10-K | 26-000016 |
| 14 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization | $22.6M | 2025-12-31 | 2026-03-03 | 10-K | 26-000016 |
| 15 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $812.0M | 2025-12-31 | 2026-03-03 | 10-K | 26-000016 |
| 16 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $16.3M | 2025-12-31 | 2026-03-03 | 10-K | 26-000016 |
| 17 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 282,579,919 | 2026-02-26 | 2026-03-03 | 10-K | 26-000016 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.